GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lantern Pharma LTRN · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.60

+5.48%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Lantern Pharma

From its filings with the US Securities and Exchange Commission

SEC filings

Lantern Pharma is based in Dallas, Texas and is incorporated in Texas. Its shares trade on Nasdaq under the ticker LTRN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $17.1m. At that date it held total assets of $11.0m and shareholders' equity of $6.5m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
11 Jun 2020
Employees
22
Head office
1920 MCKINNEY AVENUE, DALLAS, TX, 75201
Incorporated in
TX
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Donald KeyserIndependent Chairman of the Board$72,200
  • Mr. Panna SharmaPresident, Chief Executive Officer, Director, since 2018$1.1m
  • Mr. David MargraveChief Financial Officer, Secretary$752,886
  • Dr. Kishor BhatiaChief Scientific Officer$539,120
  • Dr. Lee SchalopDirector
  • Dr. Vijay ChandruIndependent Director$83,150
  • Dr. Maria MaccecchiniIndependent Director$67,200
  • Dr. David SilbersteinIndependent Director$78,150

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Lantern Pharma's RADR AI platform uses over 25 billion data points for genomic analysis.
  • The company has four drug compounds including LP-100 and LP-300 in clinical development.
  • Lantern Pharma employs 22 full-time staff focused on AI-driven drug discovery.

Weaknesses

  • The company has only two drug candidates in clinical phases out of four total compounds.
  • Lantern Pharma's portfolio includes two preclinical stage drug candidates LP-184 and LP-284.
  • Lantern Pharma's ADC program is still in research optimization phase.

Opportunities

  • Lantern Pharma's RADR AI platform can expand to new genomic data sources for better drug targeting.
  • The company can leverage its AI platform to develop more precision oncology treatments.
  • Lantern Pharma may attract partnerships with larger pharmaceutical firms for drug development.

Threats

  • Lantern Pharma faces competition from other biotech firms using AI in drug discovery.
  • The company's reliance on AI and genomic data could lead to regulatory challenges.
  • Lantern Pharma's small employee count of 22 may limit its research capacity.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.